Tesidolumab, which binds to a separate C5 epitope, and ravulizumab, which shares the same epitope on C5 with eculizumab but has longer plasma stability, have also been investigated in preliminary single-arm studies of severe COVID-19 patients (Fig. 1). Here, C5 is linked to COVID-19.